| Vijay J Nayak, DO | |
|
4320 Seminary Rd, Alexandria, VA 22304-1535 | |
| (703) 504-3000 | |
| Not Available |
| Full Name | Vijay J Nayak |
|---|---|
| Gender | Male |
| Speciality | Diagnostic Radiology |
| Experience | 12 Years |
| Location | 4320 Seminary Rd, Alexandria, Virginia |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1659628154 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2085R0202X | Radiology - Diagnostic Radiology | 0102205709 (Virginia) | Primary |
| 2085R0202X | Radiology - Diagnostic Radiology | 15425 (California) | Secondary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Kaiser Foundation Hospital - San Leandro | San leandro, CA | Hospital |
| Kaiser Foundation Hospital - Fremont | Fremont, CA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Permanente Medical Group Inc | 8921910225 | 7800 |
News Archive
Scientists at the University of Glasgow Centre for Virus Research in the United Kingdom and the South China Agricultural University in Guangzhou, China, have shed light on the animal origin of SARS-CoV-2, tracing back to the first outbreak of the severe acute respiratory syndrome coronavirus (SARS-CoV), the infectious agent of the severe acute respiratory syndrome (SARS) in China in 2002 to 2003.
The therapeutic monoclonal antibody CT-P59 binds to the RBD of SARS-CoV-2, the site of these three major mutations, which may therefore reduce the potency of this antibody against the P.1 lineage. In a new study, the neutralizing potency of this monoclonal antibody towards both wildtype and P.1 SARS-CoV-2 is investigated. The researchers found that the ability to bind with the virus is impeded by the mutations, resulting in reduced potency in vitro.
There is no evidence to support psychological debriefing in schools after traumatic events such as violence, suicides and accidental death, which runs counter to current practice in some Canadian school jurisdictions, according to a commentary http://www.cmaj.ca/embargo/cmaj091621.pdf in CMAJ (Canadian Medical Association Journal) www.cmaj.ca .
Dr. Castro is a translational oncologist with experience developing and harnessing nanotechnology and molecular imaging platforms for cancer purposes. His work offers a "less is more" approach — to generate robust cancer analyses using scant amount of specimens. Dr. Castro's research has included funding from the V Foundation for Cancer Research, National Institutes of Health, Ovarian Cancer Research Fund, and the Department of Defense.
› Verified 7 days ago
| Entity Name | Permanente Medical Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1073606299 PECOS PAC ID: 8921910225 Enrollment ID: O20031104000710 |
News Archive
Scientists at the University of Glasgow Centre for Virus Research in the United Kingdom and the South China Agricultural University in Guangzhou, China, have shed light on the animal origin of SARS-CoV-2, tracing back to the first outbreak of the severe acute respiratory syndrome coronavirus (SARS-CoV), the infectious agent of the severe acute respiratory syndrome (SARS) in China in 2002 to 2003.
The therapeutic monoclonal antibody CT-P59 binds to the RBD of SARS-CoV-2, the site of these three major mutations, which may therefore reduce the potency of this antibody against the P.1 lineage. In a new study, the neutralizing potency of this monoclonal antibody towards both wildtype and P.1 SARS-CoV-2 is investigated. The researchers found that the ability to bind with the virus is impeded by the mutations, resulting in reduced potency in vitro.
There is no evidence to support psychological debriefing in schools after traumatic events such as violence, suicides and accidental death, which runs counter to current practice in some Canadian school jurisdictions, according to a commentary http://www.cmaj.ca/embargo/cmaj091621.pdf in CMAJ (Canadian Medical Association Journal) www.cmaj.ca .
Dr. Castro is a translational oncologist with experience developing and harnessing nanotechnology and molecular imaging platforms for cancer purposes. His work offers a "less is more" approach — to generate robust cancer analyses using scant amount of specimens. Dr. Castro's research has included funding from the V Foundation for Cancer Research, National Institutes of Health, Ovarian Cancer Research Fund, and the Department of Defense.
› Verified 7 days ago
| Entity Name | University Of California Sfgh Medical Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1063487122 PECOS PAC ID: 5496668410 Enrollment ID: O20031106000503 |
News Archive
Scientists at the University of Glasgow Centre for Virus Research in the United Kingdom and the South China Agricultural University in Guangzhou, China, have shed light on the animal origin of SARS-CoV-2, tracing back to the first outbreak of the severe acute respiratory syndrome coronavirus (SARS-CoV), the infectious agent of the severe acute respiratory syndrome (SARS) in China in 2002 to 2003.
The therapeutic monoclonal antibody CT-P59 binds to the RBD of SARS-CoV-2, the site of these three major mutations, which may therefore reduce the potency of this antibody against the P.1 lineage. In a new study, the neutralizing potency of this monoclonal antibody towards both wildtype and P.1 SARS-CoV-2 is investigated. The researchers found that the ability to bind with the virus is impeded by the mutations, resulting in reduced potency in vitro.
There is no evidence to support psychological debriefing in schools after traumatic events such as violence, suicides and accidental death, which runs counter to current practice in some Canadian school jurisdictions, according to a commentary http://www.cmaj.ca/embargo/cmaj091621.pdf in CMAJ (Canadian Medical Association Journal) www.cmaj.ca .
Dr. Castro is a translational oncologist with experience developing and harnessing nanotechnology and molecular imaging platforms for cancer purposes. His work offers a "less is more" approach — to generate robust cancer analyses using scant amount of specimens. Dr. Castro's research has included funding from the V Foundation for Cancer Research, National Institutes of Health, Ovarian Cancer Research Fund, and the Department of Defense.
› Verified 7 days ago
| Entity Name | University Of California Sfgh Medical Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1760457816 PECOS PAC ID: 5496668410 Enrollment ID: O20031229000429 |
News Archive
Scientists at the University of Glasgow Centre for Virus Research in the United Kingdom and the South China Agricultural University in Guangzhou, China, have shed light on the animal origin of SARS-CoV-2, tracing back to the first outbreak of the severe acute respiratory syndrome coronavirus (SARS-CoV), the infectious agent of the severe acute respiratory syndrome (SARS) in China in 2002 to 2003.
The therapeutic monoclonal antibody CT-P59 binds to the RBD of SARS-CoV-2, the site of these three major mutations, which may therefore reduce the potency of this antibody against the P.1 lineage. In a new study, the neutralizing potency of this monoclonal antibody towards both wildtype and P.1 SARS-CoV-2 is investigated. The researchers found that the ability to bind with the virus is impeded by the mutations, resulting in reduced potency in vitro.
There is no evidence to support psychological debriefing in schools after traumatic events such as violence, suicides and accidental death, which runs counter to current practice in some Canadian school jurisdictions, according to a commentary http://www.cmaj.ca/embargo/cmaj091621.pdf in CMAJ (Canadian Medical Association Journal) www.cmaj.ca .
Dr. Castro is a translational oncologist with experience developing and harnessing nanotechnology and molecular imaging platforms for cancer purposes. His work offers a "less is more" approach — to generate robust cancer analyses using scant amount of specimens. Dr. Castro's research has included funding from the V Foundation for Cancer Research, National Institutes of Health, Ovarian Cancer Research Fund, and the Department of Defense.
› Verified 7 days ago
| Entity Name | Radadvantage A Professional Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1376719666 PECOS PAC ID: 2163597899 Enrollment ID: O20090917000455 |
News Archive
Scientists at the University of Glasgow Centre for Virus Research in the United Kingdom and the South China Agricultural University in Guangzhou, China, have shed light on the animal origin of SARS-CoV-2, tracing back to the first outbreak of the severe acute respiratory syndrome coronavirus (SARS-CoV), the infectious agent of the severe acute respiratory syndrome (SARS) in China in 2002 to 2003.
The therapeutic monoclonal antibody CT-P59 binds to the RBD of SARS-CoV-2, the site of these three major mutations, which may therefore reduce the potency of this antibody against the P.1 lineage. In a new study, the neutralizing potency of this monoclonal antibody towards both wildtype and P.1 SARS-CoV-2 is investigated. The researchers found that the ability to bind with the virus is impeded by the mutations, resulting in reduced potency in vitro.
There is no evidence to support psychological debriefing in schools after traumatic events such as violence, suicides and accidental death, which runs counter to current practice in some Canadian school jurisdictions, according to a commentary http://www.cmaj.ca/embargo/cmaj091621.pdf in CMAJ (Canadian Medical Association Journal) www.cmaj.ca .
Dr. Castro is a translational oncologist with experience developing and harnessing nanotechnology and molecular imaging platforms for cancer purposes. His work offers a "less is more" approach — to generate robust cancer analyses using scant amount of specimens. Dr. Castro's research has included funding from the V Foundation for Cancer Research, National Institutes of Health, Ovarian Cancer Research Fund, and the Department of Defense.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Vijay J Nayak, DO 8001 Forbes Pl Ste 103, Springfield, VA 22151-2205 Ph: (814) 426-7319 | Vijay J Nayak, DO 4320 Seminary Rd, Alexandria, VA 22304-1535 Ph: (703) 504-3000 |
News Archive
Scientists at the University of Glasgow Centre for Virus Research in the United Kingdom and the South China Agricultural University in Guangzhou, China, have shed light on the animal origin of SARS-CoV-2, tracing back to the first outbreak of the severe acute respiratory syndrome coronavirus (SARS-CoV), the infectious agent of the severe acute respiratory syndrome (SARS) in China in 2002 to 2003.
The therapeutic monoclonal antibody CT-P59 binds to the RBD of SARS-CoV-2, the site of these three major mutations, which may therefore reduce the potency of this antibody against the P.1 lineage. In a new study, the neutralizing potency of this monoclonal antibody towards both wildtype and P.1 SARS-CoV-2 is investigated. The researchers found that the ability to bind with the virus is impeded by the mutations, resulting in reduced potency in vitro.
There is no evidence to support psychological debriefing in schools after traumatic events such as violence, suicides and accidental death, which runs counter to current practice in some Canadian school jurisdictions, according to a commentary http://www.cmaj.ca/embargo/cmaj091621.pdf in CMAJ (Canadian Medical Association Journal) www.cmaj.ca .
Dr. Castro is a translational oncologist with experience developing and harnessing nanotechnology and molecular imaging platforms for cancer purposes. His work offers a "less is more" approach — to generate robust cancer analyses using scant amount of specimens. Dr. Castro's research has included funding from the V Foundation for Cancer Research, National Institutes of Health, Ovarian Cancer Research Fund, and the Department of Defense.
› Verified 7 days ago
Dr. Lisa Schiller Lull, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 4320 Seminary Rd, Alexandria, VA 22304 Phone: 703-504-3000 | |
Dr. Jason Shou, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 4320 Seminary Rd, Alexandria, VA 22304 Phone: 703-504-3000 | |
Ali Alikhani, MD Radiology Medicare: May Accept Medicare Assignments Practice Location: 4320 Seminary Rd, Alexandria, VA 22304 Phone: 703-504-3000 | |
William Patrick O'grady, M.D. Radiology Medicare: Not Enrolled in Medicare Practice Location: 3720 Seminary Rd, Alexandria, VA 22304 Phone: 703-751-7790 Fax: 703-823-2862 | |
Dr. Patricia Aukes Barnes, Radiology Medicare: Accepting Medicare Assignments Practice Location: 1810 Carpenter Rd, Alexandria, VA 22314 Phone: 855-687-7237 | |
Michael Kaplan, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 4320 Seminary Rd, Alexandria, VA 22304 Phone: 703-504-3000 |